WASHINGTON--(BUSINESS WIRE)--The following statement was issued by Sara Radcliffe, executive vice president for Health at the Biotechnology Industry Organization (BIO), who is scheduled to participate today in the U.S. Food and Drug Administration’s (FDA) Public Hearing on the Approval Pathway for Biosimilar and Interchangeable Biological Products:
